Background {#Sec1}
==========

Prostatic abscess is a rare complication of acute bacterial prostatitis, described in 0.5 to 2.5% of patients presenting with inflammatory prostatitis \[[@CR1]\]. Patients with prostatic abscess typically present with difficulty urinating or with acute urinary retention. The most common causative pathogens include Enterobacteriaceae such as *Escherichia coli* \[[@CR2]\], or in our local clinical context in northern Australia, *Burkholderia pseudomallei* \[[@CR3]\]. *Staphylococcus aureus*, a Gram-positive coccus, is a common human pathogen, yet is a rarely reported cause of prostatic abscess \[[@CR1]\].

We report here a case of prostatic abscess due to *S. aureus* in a man who presented to our institution and contextualise this with a literature review.

Case presentation {#Sec2}
=================

The patient was a 53 year-old Indigenous Australian who presented to a remote regional hospital in northern Australia with acute onset urinary retention. His past history included type 2 diabetes mellitus, chronic hepatitis B infection and recurrent skin and soft tissue infections. He also had a history of long-term kava use.

An indwelling urinary catheter (IDC) was inserted and culture performed of the IDC urine specimen; however, the patient refused further treatment and self-discharged the same day (following removal of the IDC). At day 2, the initial urine culture revealed methicillin-resistant *S. aureus* (MRSA).

The patient was recalled and admitted to hospital. His urinary symptoms and associated suprapubic pain persisted. He had difficulty ambulating due to pain in his left thigh. A digital rectal examination revealed a firm prostate of normal size, without tenderness, and a tender diffuse swelling was noted in the medial left thigh. A beside ultrasound of the thigh revealed a hypoechoic lesion measuring 74x52x61 mm with an estimated volume of 123 mL. The patient had blood taken for culture, was then commenced on intravenous vancomycin and then transferred by air ambulance to our institution, where he was admitted for ongoing care.

Laboratory tests on admission showed a total leucocyte count of 12.7 × 10^9^/L (neutrophil count, 8.7 × 10^9^/L) and a CRP of 65 mg/L (reference range 0.0--5.0 mg/L). Serological testing for *B. pseudomallei* was negative at \<1:20 using indirect haemagglutination. *B. pseudomallei* was not isolated from throat or rectal swabs after culture in Ashdown's medium \[[@CR4]\]. Urine culture again isolated a pure growth of MRSA, with reported antibiotic sensitivity to clindamycin but resistance to trimethroprim. This profile is consistent with non--multidrug-resistant, methicillin-resistant *S. aureus* (nmMRSA; isolates being defined phenotypically as those resistant to less than 3 non--beta lactam antibiotic classes \[[@CR5]\]). An ulcer present on the right great toe was swabbed and was also culture-positive for nmMRSA with an identical antibiogram. Skin scrapings on this admission tested positive for *Sarcoptes scabei* and his clinical condition was consistent with a concomitant diagnosis of crusted (previously, Norwegian) scabies. He also had an ulcer on his right great toe.

A CT scan of the abdomen and pelvis showed multiple prostatic abscesses including a prominent expansive abscess within the left base and multiple loculations within the apex (Additional file [1](#MOESM1){ref-type="media"}: Fig. S1).

At day 2 post-transfer, screening blood cultures isolated nmMRSA with the same antibiogram as was found in urine on the first assessment. Vancomycin Etest® showed an MIC of 1.5 μg/mL.

This patient underwent immediate surgical drainage of the thigh abscess on day 1 following transfer and at day 5 underwent trans-rectal ultrasound guided drainage of the prostate, whereupon 5 mL of purulent fluid was aspirated from the superior margin of the left lobe. The prostate aspirate and operative samples from the thigh abscess cultured nmMRSA with the same resistance profile as previously; *B. pseudomallei* was not isolated. The collections of fluid in the right lobe of the prostate were unable to be drained because of their small size, anatomical location and thickness of the wall of the prostate.

A follow-up CT scan post-drainage of the prostatic abscess showed interval improvement in the loculated right prostatic abscess; however, the left-sided collection appeared unchanged with possible enlargement (Additional file [2](#MOESM2){ref-type="media"}: Fig. S2), measuring 21 × 35 mm compared with 19 × 21 mm prior to drainage. Following three days of IV antibiotic therapy and following surgical drainage of the abscess, surveillance blood cultures were negative. Transthoracic echocardiogram showed no evidence of endocarditis.

The patient was continued on intravenous vancomycin with addition of oral clindamycin because of its recognised prostatic penetration \[[@CR6]\]. He declined further surgical drainage options. The patient improved clinically and received a total 4 weeks of intravenous vancomycin plus oral clindamycin therapy. Repeat imaging at the completion of IV therapy showed some residual abscess collection (not shown). Further surgical intervention was discussed with the patient and was declined. Repeat imaging performed 5 months later showed the prostatic abscess had completely resolved.

Molecular microbiological genotype of disease {#Sec3}
---------------------------------------------

The *S. aureus* isolates recovered from the blood cultures and an additional isolate recovered from the prostate aspirate underwent molecular genotyping as previously described \[[@CR7]\]. The isolates genotyped as Clonal Complex (CC) 5. Notably, *lukPV* (encoding for Panton-Valentine leucocidin \[PVL\]) was detected by PCR in both isolates.

Literature review {#Sec4}
=================

Methods {#Sec5}
-------

Two investigators independently and in duplicate conducted a review of the literature searching the MEDLINE and Cochrane databases for the terms "(prostate OR prostatic) AND aureus AND abscess\*" from January 1946 through January 2017 inclusive to identify all relevant published literature. Non-MEDLINE indexed literature was also consulted and citation searching was undertaken on all results to identify further studies. Results were limited to peer-reviewed publications in English. Approval for this case report and study was granted by the Human Research Ethics Committee of the Northern Territory Department of Health and the Menzies School of Health Research (HREC number 2015--2457).

Results {#Sec6}
=======

Thirty nine publications were identified. After screening the titles and abstracts, 21 publications met the inclusion criteria and were thus eligible for full-text review. An additional 14 papers were identified by reference screening for further citations that met inclusion criteria. The case presented in this study has been added to studies identified in the review.

These 35 full-text papers included a total of 39 patients with a diagnosis of *S. aureus* prostatic abscess. With our report of a further case, this led to a review of 40 cases. The summary of the literature search is displayed in Table [1](#Tab1){ref-type="table"}.Table 1Summary of the current literature on *S. aureus* prostatic abscessRefAgeSusceptibilityPresentationRisk FactorsBacteremiaDrainageAntibiotic UsedOutcome\[[@CR8]\]42MRSADysuria, urinary retention, abdominal painUrinary retentionNoTransrectalLevofloxacin, metronidazole, fluconazoleResolution\[[@CR14]\]31MRSADysuria, abdominal painImmunosuppression, recent IDC, T2DM, liver transplantYesNo drainage.Vancomycin, ceftriaxone, daptomycinResolution\[[@CR15]\]20MSSA + PVLDysuriaNoneYesTransrectalCeftriaxone, amikacin, ciprofloxacin, rifampicin, ofloxacin, fosfomycinResolution\[[@CR16]\]56MRSADysuria, polyuria, difficulty urinatingDiabetes mellitusNoRadiology guided then TURPVancomycinResolution\[[@CR17]\]47MRSADiffuse myalgias, dry cough, anorexia, dyspnea, fever, and chillsRecent penile furuncle, history of hypospadias with urethral strictureNoNo drainageVancomycin, piperacillin/tazobactamDeath\[[@CR17]\]31MRSALeft-sided pleuritic chest pain, fevers, rigors, and fatigueSickle betaYesTransrectal and TURPVancomycin, piperacillin/tazobactam, daptomycin, TMP-SMXResolution\[[@CR18]\]52MRSAAbdominal pain, urinary frequencyDiabetes mellitusYesTURPVancomycin, TMP-SMX, rifampinResolution\[[@CR19]\]47MRSADysuria, pyrexia, urinary frequency, rectal tenesmus, right flank painNoneNoTURPVancomycin, piperacillin-tazobactam, linezolid.Resolution\[[@CR19]\]20MRSAPyrexia, lower abdominal pain and perineal discomfortIVDU, hepatitis CNoTransurethralVancomycin, piperacillin-tazobactam, linezolidResolution\[[@CR20]\]49MRSADysuria, urinary retention, pyrexia, scrotal pain and oedema, constipationBPHNoTURPVancomycinResolution\[[@CR21]\]15MRSALeft buttock pain, constipation and difficulty ambulatingPrevious bilateral lower extremity and back abscesses - grew MRSANoTURPClindamycin, piperacillin-tazobactam, then vancomycin, linezolidResolution\[[@CR22]\]49MRSADifficulty urinating, low back painDiabetes mellitusYesTURPVancomycin, doxycyclineResolution\[[@CR23]\]65MSSADysuria, flank pain, and urinary retention, constipation, suprapubic painDiabetes mellitusYesTransurethral drainage.Ceftriaxone, ciprofloxacinResolution\[[@CR24]\]45MRSADysuria, perineal discomfort, rectal tenesmus and intermittent pyrexiaDiabetes mellitusYesPercutaneous, TURPVancomycinResolution\[[@CR25]\]59MRSADysuria, urinary frequency, pyrexia, rectal and perineal painDiabetes mellitus, alcoholismYesPercutaneousVancomycin, TMP-SMX, ciprofloxacinResolution\[[@CR26]\]40MRSAFever, urinary hesitancy, intermittent abdominal painHIVYesTransperinealVancomycin, gentamicinResolution\[[@CR27]\]50MSSAUrinary retentionDiabetes mellitus, alcoholismNoNo drainageCiprofloxacinResolution\[[@CR28]\]51MRSADysuria, fever, suprapubic painHIV, sepsis, adult respiratory distress syndrome, and renal failureYesTransurethralVancomycin, ciprofloxacin, TMP-SMXDeath\[[@CR29]\]64MRSADysuria,fatigue, anorexia, and weight lossDiabetes mellitusYesPercutaneousVancomycinResolution\[[@CR30]\]55MRSAUrinary hesitancy and rectal painBPHYes.No DrainageVancomycinResolution\[[@CR31]\]56MRSADifficulty urinating, hematuria, fever, chills and low back painDiabetes mellitus, BPH, history of self-digital rectal examinationsYes.Percutaneous, TURPVancomycin, rifampinResolution\[[@CR32]\]29MRSAPersistent pyrexia and superficial skin abscesses on his left calf. Worsening suprapubic and perineal painStraddle injury to urethra, urethroplasty, hepatitis CNoCope loop catheter placementVancomycinResolution\[[@CR33]\]43MRSADysuria, hesitancy, slow stream, night sweats, flushing, and perineal painIntravenous drug abuse, hepatitis CYesTURPVancomycin, nafcillin, TMP-SMXResolution\[[@CR34]\]63MRSAUrinary retention, pyrexiaRecent scrotal drainage, T2DMYesPercutaneous, TURPVancomycinUnknown\[[@CR35]\]59SA \[unknown susceptibility\]Difficulty passing urineRecent salivary gland abscess treated with antibioticsNoTransperineal, TURPCiprofloxacin, erythromycinResolution\[[@CR36]\]35SA"clinical acute prostatitis"HIV, bilateral renal abscessesNoNo drainage"IV antibiotics"Resolution\[[@CR37]\]42MSSADysuria. urethral discharge, perineal painNoNoTransperinealOxytetracyclineResolution\[[@CR38]\]43SA \[unknown susceptibility\]Dysuria, haematuria, pyrexia, purulent dischargeRecent pelvic infection and pelvic surgeryNoTransurethralGentamicin, carbenicillin.Resolution after relapse\[[@CR9]\]54MSSAPerineal painMycosis fungoidesNoTransperineal, TURPOxacillin, tobramycinResolution\[[@CR39]\]53MRSAUrinary urgency, fatigue, chills, rigors, and feverDiabetes mellitus, ObesityYesNo drainageVancomycin, TMP-SMX, rifampinResolution\[[@CR40]\]50MRSA + PVLAbdominal pain, cough, fever, weight loss, malaiseDiabetes mellitusYesCT guided drainageVancomycin, levofloxacin, daptomycinResolution\[[@CR41]\]46MRSAAcute urinary retention, dysuria, constipationInstrumentationYesTransurethralIV AntibioticsResolution\[[@CR42]\]57MRSADysuria, haematuria, pyrexiaDiabetes MellitusYesTURPCeftriaxone, vancomycinResolution\[[@CR43]\]67SA\[unknown susceptibility\]Acute urinary retention, perineal pain, dysuria, pyrexiaDiabetes mellitusYesNo drainageCiprofloxacinResolution\[[@CR44]\]12SA \[unknown susceptibility\]Acute urinary retention, pyrexiaNone-Transurethral"anti-bacterials"Resolution\[[@CR45]\]69SA \[unknown susceptibility\]Pyrexia, lethargy and problems voidingDiabetes mellitusYesTransurethralAmpicillin, oxacillinResolution\[[@CR46]\]NewbornMSSAUrinary retentionNoNoNo drainageNo therapyResolution\[[@CR46]\]14 daysMSSAUrinary retention, diarrhoea, bladder distensionNoNoOpen drainageNo therapyResolution\[[@CR46]\]3 weeksMSSAAbdominal distensionHirschsprung's diseaseYesOpen drainageNo therapyDeathThis case52nmMRSA + PVLUrinary retentionDiabetes mellitus, crusted scabies, long term kava useYesTransrectalVancomycin, clindamycinResolutionLegend: BPH \[Benign Prostatic Hypertrophy\]; CT \[Computed Tomography\]; HIV \[human immunodeficiency virus\]; IDC \[Indwelling catheter\]; IV \[Intravenous\]; PVL \[Panton Valentine leucocidin\]; SA \[*Staphylococcus aureus*\]; MSSA \[Methicillin-sensitive *Staphylococcus aureus*\]; nmMRSA \[non--multidrug-resistant, methicillin-resistant *Staphylococcus aureus*\]; MRSA \[Methicillin-resistant *Staphylococcus aureus*\]; T2DM \[Type 2 Diabetes mellitus\]; TMP-SMX \[Trimethoprim/sulfamethoxazole\]; TURP \[transurethral resection of the prostate\]

Clinical presentation {#Sec7}
---------------------

The most common clinical presentations of prostatic abscess in this population were pain (abdominal or perineal) and pyrexia. This was followed by dysuria and urinary retention (Table [2](#Tab2){ref-type="table"}). In our case, the presenting complaint was similar to those in previously published cases.Table 2Symptoms in patients with *S. aureus* prostatic abscessSymptomTotal No. Patients (40)% Of PatientsPain/discomfort2152.5%Pyrexia2050%Dysuria1742.5%Urinary retention1127.5%Difficulty micturating820%

MRSA was the dominant strain type causing prostatic abscess in the published literature, being identified in 26 (65%) cases of disease, including in the case that we report here. MSSA was identified as the causative strain in 8 cases. In 6 cases, the susceptibility of the causative bacterium was unreported. Genes encoding for PVL were identified in 3 cases, most notably in our case; however, there is little detail on how frequently the presence of *lukSF-PV* was sought in the existing literature.

Risk factors for developing *S. aureus* prostatic abscess {#Sec8}
---------------------------------------------------------

Risk factors observed in this population of *S. aureus* associated prostatic abscesses include: diabetes mellitus, prior urethral instrumentation or catheterisation, prostatitis, and immunocompromise (Table [3](#Tab3){ref-type="table"}).Table 3Risk Factors in patients with *S. aureus* prostatic abscessRisk factorTotal No. Patients (40)% Of PatientsDiabetes mellitus1742.5%History of urological disease512.5%Recent surgery/instrumentation512.5%Immunosuppression (inc. HIV)410%Hepatitis C37.5%

Bacteraemia {#Sec9}
-----------

23/40 (57.5%) cases in this report had positive blood culture results for *S. aureus* but due to variable quality of reporting in the literature, we are unable to determine if all cases had blood cultures taken*.* In addition one patient \[[@CR8]\] had urinary cultures positive for *Candida albicans* and one patient \[[@CR9]\] was co-infected with *E. coli*, *Bacteroides* and *Klebsiella pneumoniae*.

Treatment {#Sec10}
---------

The majority of patients identified were treated with antibiotic therapy, most commonly with vancomycin. 22/40 (55%) patients were treated with antibiotic combinations, 15/40 (37.5%) were treated with mono-therapy and 3/40 (7.5%) with no antibiotic therapy (Table [4](#Tab4){ref-type="table"}). In those patients with *S. aureus* bacteraemia (SAB), in addition to prostatic disease, vancomycin was again the most frequently used antibiotic, in keeping with international guidelines \[[@CR10]\].Table 4Antibiotic Choice in patients with *S. aureus* prostatic abscessAntibioticTotal No. Patients \[[@CR44]\]% PatientsVancomycin2460%Trimethoprim/Sulfamethoxaxole615%Ciprofloxacin717.5%Piperacillin + Tazobactam512.5%Rifampin410%Cefriaxone410%Linezolid37.5%Daptomycin37.5%

There is a paucity of evidence regarding the role of drainage in the treatment of prostatic abscess. In our review, 26/40 (65%) cases underwent drainage (Table [5](#Tab5){ref-type="table"}). Several patients required drainage on more than one occasion. On each of those occasions, a trans-rectal or trans-perineal approach was followed by a transurethral approach to achieve successful drainage.Table 5Method of drainage in patients with *S. aureus* prostatic abscessDrainageTotal No. Patients (40)% Of PatientsTransurethral drainage2255%Percutaneous drainage820%No drainage820%Transperineal drainage512.5%Transrectal drainage410%

Clinical outcome, microbiological outcome and relapse {#Sec11}
-----------------------------------------------------

In this review, 36/40 (90%) of cases identified resolved, one of which was following an initial relapse. Three cases died and the outcome in one case was unknown.

Discussion {#Sec12}
==========

*S. aureus* is a major human pathogen that causes a wide range of clinical infections and there is a heavy burden of staphylococcal disease in Indigenous people \[[@CR5]\]. Prostatic abscess resulting from *S. aureus* infection is very uncommon relative to its propensity to cause other human infections, with only 39 cases previously reported in the English language literature.

We have reported a case from our institution that had a common presentation of urinary retention as well as numerous risk factors identified in our literature search. These included diabetes mellitus, instrumentation of the urinary tract, and bladder outlet obstruction. Both the diagnosis of crusted scabies and a great toe ulcer are risk factors for bacteraemia and in the absence of chronicity, one of these percutaneous routes is likely to have been a source for his *S. aureus* bacteraemia and prostatic abscess.

The *S. aureus* isolates in this case were genotyped as CC5-MRSA and carried genes for the bi-component leukocidin PVL and was resistant to trimethoprim. This has similar genotypic properties to an emerging clone in the neighbouring jurisdiction of north Western Australia \[[@CR11]\].

From a limited sample size, it appears that with prompt identification, diagnosis and management, this condition is treatable with a low case fatality rate. However, there are no guidelines for management of *S. aureus* prostatic abscess. Treatment of prostatic abscesses usually involves the use of broad-spectrum antibiotics directed at Enterobacteriaceae, with or without drainage. In our experience the decision to drain an abscess depends on several factors: the size of the abscess, accessibility and ease of drainage, and the patient's response to antibiotic therapy. The sample size of this study and methodology involved means that we cannot draw firm conclusions on the evidential basis of draining prostatic abscesses caused by *S. aureus*. A single-centre retrospective study of drainage in prostatic abscess recommended that trans-rectal drainage is the best option for drainage in selected cases of prostatic abscess \[[@CR12]\].

Our case is the first report of using clindamycin step-down therapy following IV therapy. Our use of clindamycin was driven by its excellent prostatic penetration, in which prostatic levels of clindamycin have been reported to exceed that of serum levels \[[@CR13]\]. Options for drainage of prostatic abscess include trans-rectal, trans-perineal or transurethral approaches. In the case we reported here, the abscess was drained trans-rectally and was uncomplicated in this patient.

Further research {#Sec13}
----------------

There is variable consistency in what was reported in the literature and this made it difficult to synthesise the results to make recommendations for practice. Further research and reporting of *S. aureus* prostatic abscess with a standardised approach is required for understanding the pathogenesis and treatment of this uncommon condition. In this study, we have reported correlations between risk factors and the development of *S. aureus* prostatic abscess.

Conclusions {#Sec14}
===========

Prostatic abscess is an uncommonly reported manifestation of *S. aureus* infection that has a non-specific clinical presentation, which can include abdominal and/or urinary symptoms. Most published cases have been due to MRSA. Specific risk factors include diabetes mellitus, immunosuppression, instrumentation of the urinary tract, and bladder outlet obstruction. Drainage is likely to accelerate cure but the optimal method remains undefined. While there are no published guidelines, clindamycin may be particularly useful for directed therapy of susceptible organisms given its excellent prostate penetration (along with bactericidal antibiotics in cases with bacteraemia).

Additional files
================

 {#Sec15}

Additional file 1: Figure S1.CT of pelvis showing prostatic abscess in the left lobe of the prostate. (PNG 477 kb) Additional file 2: Figure S2.CT of pelvis showing persistence of prostatic abscess in the left lobe of the prostate. (PNG 447 kb)
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